Savara Inc (SVRA)

$5.66 +0.14 (2.54%)
Market Cap 1.10B
Revenue (ttm) 0.00
Net Income (ttm) -95.88M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 1,274,500
Avg Vol 2,673,716
Day's Range N/A - N/A
Shares Out 203.47M
Stochastic %K 28%
Beta 0.28
Analysts Strong Sell
Price Target $10.81

Company Profile

Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. The company's lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company was founded in 2007 and is headquartered in Langhorne, Pennsylvania.

Industry: Biotechnology
Sector: Healthcare
Phone: 512 614 1848
Address:
1717 Langhorne Newtown Road, Suite 300, Langhorne, United States
Spacemonkey1
Spacemonkey1 Feb. 3 at 9:57 PM
$SVRA FDA is still the wild card here, like everything else government currently, totally unpredictable
0 · Reply
Richterscale
Richterscale Feb. 3 at 8:01 PM
$SVRA Any thoughts on the odds we get news in February? Or too soon?
1 · Reply
sionist
sionist Feb. 3 at 11:33 AM
$SVRA done it
0 · Reply
Richterscale
Richterscale Feb. 2 at 9:20 PM
$SVRA The AH volume is crazy
0 · Reply
sionist
sionist Feb. 2 at 10:50 AM
$UNCY onyl inspection is needed. In other words, it is over as long as the factory inspection schedule is set. There are no other documents to review. Move like $SVRA
2 · Reply
Richterscale
Richterscale Jan. 30 at 4:01 PM
$SVRA Can we get 1 F ing Green Day?!
0 · Reply
Richterscale
Richterscale Jan. 28 at 5:06 PM
$SVRA This is wild how the SP continues to move around/down.
1 · Reply
trader2360
trader2360 Jan. 27 at 1:11 PM
$SVRA SVRA Savara Announces Amendment to Hercules Capital Debt Facility Providing up to $75M of Additional Debt Funding Upon U.S. Food and Drug Administration (FDA) Approval of MOLBREEVI*
0 · Reply
art62
art62 Jan. 27 at 10:10 AM
$SVRA my neck hurts, whiplash.
0 · Reply
Richterscale
Richterscale Jan. 26 at 7:27 PM
$SVRA WTF!
0 · Reply
Latest News on SVRA
Savara Announces Amendment to Hercules Capital Debt Facility Providing up to $75M of Additional Debt Funding Upon U.S. Food and Drug Administration (FDA) Approval of MOLBREEVI*

Jan 27, 2026, 8:05 AM EST - 7 days ago

Savara Announces Amendment to Hercules Capital Debt Facility Providing up to $75M of Additional Debt Funding Upon U.S. Food and Drug Administration (FDA) Approval of MOLBREEVI*

HTGC

Savara Announces New Employment Inducement Grant

Jan 16, 2026, 4:05 PM EST - 18 days ago

Savara Announces New Employment Inducement Grant

Savara Inc. (SVRA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 15, 2026, 5:16 AM EST - 19 days ago

Savara Inc. (SVRA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

PANTHERx® Rare Selected by Savara as the U.S. Exclusive Specialty Pharmacy for MOLBREEVI*

Jan 8, 2026, 4:05 PM EST - 26 days ago

PANTHERx® Rare Selected by Savara as the U.S. Exclusive Specialty Pharmacy for MOLBREEVI*

Savara Resubmits the Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for MOLBREEVI* for the Potential Treatment of Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)

Dec 22, 2025, 8:30 AM EST - 6 weeks ago

Savara Resubmits the Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for MOLBREEVI* for the Potential Treatment of Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)

Savara Announces Participation in the 44th Annual J.P. Morgan Healthcare Conference

Dec 17, 2025, 8:05 AM EST - 6 weeks ago

Savara Announces Participation in the 44th Annual J.P. Morgan Healthcare Conference

Savara Announces European Patent Office (EPO) Intends to Grant a Patent for the Liquid Formulation of MOLBREEVI*

Dec 11, 2025, 8:05 AM EST - 7 weeks ago

Savara Announces European Patent Office (EPO) Intends to Grant a Patent for the Liquid Formulation of MOLBREEVI*

Savara and PARI Granted a European Patent Covering the Drug-Device Combination of MOLBREEVI* Delivered Via the Proprietary eFlow® Nebulizer System

Dec 2, 2025, 8:05 AM EST - 2 months ago

Savara and PARI Granted a European Patent Covering the Drug-Device Combination of MOLBREEVI* Delivered Via the Proprietary eFlow® Nebulizer System

Savara Announces Participation in Upcoming Investor Healthcare Conferences

Nov 20, 2025, 4:05 PM EST - 2 months ago

Savara Announces Participation in Upcoming Investor Healthcare Conferences

Savara: A High-Risk Opportunity

Nov 16, 2025, 6:35 AM EST - 2 months ago

Savara: A High-Risk Opportunity

Savara Reports Third Quarter 2025 Financial Results and Provides Business Update

Nov 12, 2025, 4:05 PM EST - 2 months ago

Savara Reports Third Quarter 2025 Financial Results and Provides Business Update

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of November 7, 2025 in Savara Inc. Lawsuit – SVRA

Nov 5, 2025, 5:54 PM EST - 3 months ago

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of November 7, 2025 in Savara Inc. Lawsuit – SVRA

Savara Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Total Gross Proceeds of $149.5M

Oct 31, 2025, 4:05 PM EDT - 3 months ago

Savara Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Total Gross Proceeds of $149.5M

SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Savara

Oct 30, 2025, 11:05 AM EDT - 3 months ago

SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Savara

Savara Announces Pricing of $130.0 Million Public Offering of Common Stock and Pre-funded Warrants

Oct 29, 2025, 9:43 PM EDT - 3 months ago

Savara Announces Pricing of $130.0 Million Public Offering of Common Stock and Pre-funded Warrants

Savara Announces Proposed Public Offering

Oct 29, 2025, 4:07 PM EDT - 3 months ago

Savara Announces Proposed Public Offering

Savara announces $75M Royalty Funding Agreement with RTW to Support the Potential Launch of MOLBREEVI* in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)

Oct 29, 2025, 4:01 PM EDT - 3 months ago

Savara announces $75M Royalty Funding Agreement with RTW to Support the Potential Launch of MOLBREEVI* in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Savara

Oct 28, 2025, 9:58 AM EDT - 3 months ago

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Savara

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Savara

Oct 23, 2025, 1:36 PM EDT - 3 months ago

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Savara

Savara Announces Chief Medical Officer (CMO) Transition

Oct 17, 2025, 8:05 AM EDT - 3 months ago

Savara Announces Chief Medical Officer (CMO) Transition

SAVARA DEADLINE REMINDER: Bragar Eagel & Squire, P.C. Reminds Savara Investors to Contact the Firm Before the November 7th Deadline

Oct 14, 2025, 12:14 PM EDT - 4 months ago

SAVARA DEADLINE REMINDER: Bragar Eagel & Squire, P.C. Reminds Savara Investors to Contact the Firm Before the November 7th Deadline

SVRA INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Savara

Oct 12, 2025, 8:44 AM EDT - 4 months ago

SVRA INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Savara

Savara: Back On Track With Upcoming APAP BLA Filing

Oct 9, 2025, 7:42 AM EDT - 4 months ago

Savara: Back On Track With Upcoming APAP BLA Filing

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of November 7, 2025 in Savara Inc. Lawsuit - SVRA

Oct 6, 2025, 8:45 AM EDT - 4 months ago

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of November 7, 2025 in Savara Inc. Lawsuit - SVRA

Savara Announces Encore Presentations of Results From the Phase 3 IMPALA-2 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at CHEST 2025

Oct 2, 2025, 4:05 PM EDT - 4 months ago

Savara Announces Encore Presentations of Results From the Phase 3 IMPALA-2 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at CHEST 2025

Savara Presents New Data From the Phase 3 IMPALA-2 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the European Respiratory Society (ERS) Congress 2025

Sep 29, 2025, 2:00 AM EDT - 4 months ago

Savara Presents New Data From the Phase 3 IMPALA-2 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the European Respiratory Society (ERS) Congress 2025

Savara Announces New U.S. Health Claims Data Analysis Finds Over 50% Increase in the Estimated Number of Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP) Patients Compared to Previous Claims Analysis

Sep 2, 2025, 9:00 AM EDT - 5 months ago

Savara Announces New U.S. Health Claims Data Analysis Finds Over 50% Increase in the Estimated Number of Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP) Patients Compared to Previous Claims Analysis

New England Journal of Medicine (NEJM) to Publish Results From Savara's Pivotal Phase 3 IMPALA-2 Clinical Trial in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)

Aug 20, 2025, 5:15 PM EDT - 5 months ago

New England Journal of Medicine (NEJM) to Publish Results From Savara's Pivotal Phase 3 IMPALA-2 Clinical Trial in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)

Savara to Present New Data from the Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the European Respiratory Society Congress 2025

Aug 18, 2025, 8:05 AM EDT - 6 months ago

Savara to Present New Data from the Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the European Respiratory Society Congress 2025

Savara Reports Second Quarter 2025 Financial Results and Provides a Business Update

Aug 13, 2025, 8:05 AM EDT - 6 months ago

Savara Reports Second Quarter 2025 Financial Results and Provides a Business Update

Spacemonkey1
Spacemonkey1 Feb. 3 at 9:57 PM
$SVRA FDA is still the wild card here, like everything else government currently, totally unpredictable
0 · Reply
Richterscale
Richterscale Feb. 3 at 8:01 PM
$SVRA Any thoughts on the odds we get news in February? Or too soon?
1 · Reply
sionist
sionist Feb. 3 at 11:33 AM
$SVRA done it
0 · Reply
Richterscale
Richterscale Feb. 2 at 9:20 PM
$SVRA The AH volume is crazy
0 · Reply
sionist
sionist Feb. 2 at 10:50 AM
$UNCY onyl inspection is needed. In other words, it is over as long as the factory inspection schedule is set. There are no other documents to review. Move like $SVRA
2 · Reply
Richterscale
Richterscale Jan. 30 at 4:01 PM
$SVRA Can we get 1 F ing Green Day?!
0 · Reply
Richterscale
Richterscale Jan. 28 at 5:06 PM
$SVRA This is wild how the SP continues to move around/down.
1 · Reply
trader2360
trader2360 Jan. 27 at 1:11 PM
$SVRA SVRA Savara Announces Amendment to Hercules Capital Debt Facility Providing up to $75M of Additional Debt Funding Upon U.S. Food and Drug Administration (FDA) Approval of MOLBREEVI*
0 · Reply
art62
art62 Jan. 27 at 10:10 AM
$SVRA my neck hurts, whiplash.
0 · Reply
Richterscale
Richterscale Jan. 26 at 7:27 PM
$SVRA WTF!
0 · Reply
BillionerOfKing
BillionerOfKing Jan. 25 at 3:52 AM
$SVRA Current Stock Price: $6.01 Contracts to trade: $5 SVRA Feb 20 2026 Call Entry: $0.05 Exit: $0.07 ROI: 39% Hold ~25 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
Richterscale
Richterscale Jan. 23 at 4:03 AM
$SVRA On 1/21 BlackRock increased holdings
0 · Reply
Richterscale
Richterscale Jan. 22 at 9:34 PM
$SVRA Solid day
0 · Reply
art62
art62 Jan. 22 at 3:01 PM
$SVRA news i might have missed? or just FEB BLA anticipation?
2 · Reply
Richterscale
Richterscale Jan. 15 at 7:27 PM
$SVRA So it wasn’t a good meeting last night?
0 · Reply
SwingTradeWithJ
SwingTradeWithJ Jan. 15 at 1:11 AM
$SVRA Entered long on EMA Trend Support setup. Price reclaimed and is holding above 21/34 EMAs with 2 consecutive green daily candles, confirming higher low + higher high. Momentum improving (MACD curling up, RSI neutral-bullish with room). Looking for continuation toward $7.20 as long as EMAs hold. Risk defined below recent higher low.
0 · Reply
Richterscale
Richterscale Jan. 12 at 8:56 PM
$SVRA https://www.businesswire.com/news/home/20251217079438/en/
1 · Reply
Richterscale
Richterscale Jan. 12 at 7:16 PM
$SVRA This usually makes a little run to a conference guess we r now in a holding pattern until we news
1 · Reply
ghostdemon
ghostdemon Jan. 12 at 3:48 PM
$SVRA 😂😂😂
0 · Reply
ckruel
ckruel Jan. 9 at 8:14 PM
$SVRA Savara, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Francois Brisebois from LifeSci Capital maintained a Buy rating on the stock and has a $11.00 price target.
0 · Reply
ckruel
ckruel Jan. 9 at 2:45 PM
$SVRA • Savara updated its corporate materials to spotlight autoimmune PAP and related unmet needs. • The presentation underscores high disease burden and supports Savara’s rare respiratory focus.
0 · Reply
11thestate
11thestate Jan. 9 at 12:31 PM
When we see a stock like this, we know how many damaged investors are out there. Believe it or not, there’s some good news. $SVRA investors — you might be surprised, but you actually have a chance to recover your losses. Don’t miss it: https://11th.com/cases/savara-investor-suit
0 · Reply